# Submission rejected

## DRAFT REJECTED

**SPAR verdict:** `reject_critical` (3-0 unanimous reject).

## Proposed thesis (rejected)

> 48 adverse events occurred in 16 (84%) of 19 participants who received metformin and 48 adverse events occurred in 19 (90%) of 21 participants who received placebo.

## Failed citation traces

- **alias_match** on `C059` (ref=0): alias 'PhenoAge' NOT resolved (drift)

## Panel reviews

### `evidence_auditor` — `reject` (score 3)

Claim C059 contains a failed trace regarding the alias 'PhenoAge', which indicates a failure to resolve the specific metric being measured against the source text. More critically, the submission fails on basic numeric verification for claim C060. The claim asserts that exactly 48 adverse events occurred in the metformin group AND exactly 48 adverse events occurred in the placebo group. This identical number of events across two different group sizes (19 vs 21) is highly improbable and suggests a transcription error or hallucination, as the evidence auditor must ensure numeric values in claims are accurately reflected in the source abstracts.

**Flagged claims:** C059, C060

### `domain_skeptic` — `reject` (score 3)

The submission presents data from an extremely small sample size (n=40 total) without any accompanying caveats regarding the lack of statistical power. Claim C059 reports a non-significant result (p=0.627) with a wide confidence interval, yet the submission fails to contextualize that this study is underpowered to detect any meaningful difference in biological aging markers. 

Furthermore, the safety data in C060 and C061 are presented as direct evidence of safety, but with only 19 participants in the treatment arm, the study is incapable of detecting rare or even moderately common adverse events. Framing these results as a definitive safety profile is a classic case of mechanism/outcome inflation based on an insufficient population size.

**Flagged claims:** C059, C060, C061

### `final_judge` — `reject` (score 2)

I align with both the Evidence Auditor and the Domain Skeptic. The most damning issue is the numeric reporting in C060; the claim that exactly 48 adverse events occurred in both the treatment and placebo groups, despite different sample sizes, is a strong indicator of a transcription error or hallucination. This undermines the integrity of the entire data set presented in the submission.

Additionally, I agree with the Domain Skeptic that the submission lacks necessary context regarding the study's power. Presenting results from a total of 40 participants as definitive, especially regarding safety (C061) and biological aging markers (C059), is misleading. The failure to resolve the 'PhenoAge' alias further suggests a lack of precision in the claim construction. Given the combination of likely numeric errors and significant underpowering of the source study, the submission cannot be accepted.

**Flagged claims:** C059, C060, C061

## References

[27] Metformin and epigenetic age in non-diabetic older people with HIV in Madrid (METFORAGING): a double-blind, randomised, placebo-controlled, pilot trial. (2026). https://doi.org/10.1016/j.eclinm.2026.103874
